Structure Therapeutics Inc.
Close on Oct 19, 2026
- Market cap
- $4.80B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | During market hours | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | During market hours | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | During market hours | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | During market hours | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | During market hours | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | During market hours | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | During market hours | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | During market hours | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 8, 2024 | Before market open | – | – | – |
Press releases
Announcements Structure Therapeutics filed with the SEC
Structure Therapeutics Reports Positive Clinical
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
1 Amylin and GLP - 1 Program Updates September 8, 2026
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Structure Therapeutics Reports Second Quarter
Results of operations · EX-99.1 to Form 8-K
Reports First Quarter 2026 Financial Results and Recent Highlights
Material agreement · Results of operations · Other events · EX-99.1 to Form 8-K
Structure Therapeutics Appoints Matthew Lang,
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Structure Therapeutics Reports Positive Topline
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Structure Therapeutics Reports Fourth Quarter
Results of operations · EX-99.1 to Form 8-K
Structure Therapeutics Reports Positive Topline
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Structure Therapeutics Reports Third Quarter
Results of operations · EX-99.1 to Form 8-K
Structure Therapeutics Reports Second Quarter
Results of operations · EX-99.1 to Form 8-K
Structure Therapeutics Reports First Quarter
Results of operations · EX-99.1 to Form 8-K
Structure Therapeutics Reports Fourth Quarter
Results of operations · EX-99.1 to Form 8-K
Announces Selection of Lead Oral Small Molecule
Regulation FD disclosure · EX-99.1 to Form 8-K
Structure Therapeutics Reports Third Quarter
Results of operations · EX-99.1 to Form 8-K
Promotion of Blai Coll, M.D., Ph.D. to Chief
Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Structure Therapeutics Reports Second Quarter
Results of operations · EX-99.1 to Form 8-K
of the date of this Current Report, Structure Therapeutics Inc. (the “Company”) updates and supplements the risk factors disclosed
Other events · EX-99.1 to Form 8-K
Structure Therapeutics Reports Positive Topline
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Disclaimers and Forward Looking Statements
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Structure Therapeutics Reports First Quarter
Results of operations · EX-99.1 to Form 8-K
Structure Therapeutics Reports Fourth Quarter
Results of operations · EX-99.1 to Form 8-K
Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
GSBR - 1290 Comprehensive Program Update CONFIDENTIAL December 18, 2023
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Reports Third Quarter 2023 Financial Results and Recent Highlights
Material agreement · Results of operations · EX-99.1 to Form 8-K
(this “ Agreement ”) is dated as of September 29, 2023, by and among Structure Therapeutics, Inc., an exempted
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Structure Therapeutics Announces $300 Million
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
Structure Therapeutics Announces Positive Results
Regulation FD disclosure · EX-99.1 to Form 8-K
GSBR-1290 Phase 1b MAD Results
Regulation FD disclosure · EX-99.2 to Form 8-K
Structure Therapeutics Reports Second Quarter
Results of operations · EX-99.1 to Form 8-K
Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
Results of operations · EX-99.1 to Form 8-K
Structure Therapeutics Reports Fourth Quarter
Results of operations · EX-99.1 to Form 8-K